Amgen, Inc.’s third quarter financials generally met or beat analyst consensus despite COVID-19 impacts on individual product sales and the company essentially maintained its revenue guidance for 2020. However, investors’ biggest questions going into Amgen’s 28 October earnings call about three key late-stage programs remained unanswered.
The company did not say whether it will seek accelerated approval from the US Food and Drug Administration for sotorasib (AMG 510) in the treatment of non-small cell lung cancer...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?